You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • Correction: Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice

https://doi.org/10.1136/rmdopen-2023-003270corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Tanaka Y. Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice. RMD Open 2023;9:e003270. doi: 10.1136/rmdopen-2023-003270

    Updates have been made to the 2nd paragraph under the following section: Patients with moderate to severe SLE who are unable to achieve at least LLDAS with existing SoC treatments.

    Original paragraph

    In a post hoc analysis of the pooled TULIP-1/TULIP-2 trials, 15.3% of anifrolumab-treated patients (300 mg every 4 weeks (Q4W)) achieved DORIS remission at Week 52, compared with 7.6% of patients treated with placebo (odds ratio (OR) (95% CI): 2.2 (1.4 to 3.6), p=0.0013). DORIS remission was achieved by significantly more patients in the anifrolumab group compared with the placebo group starting at Week 32, suggesting an earlier attainment of DORIS remission with anifrolumab treatment.

    Revised paragraph

    In a post hoc analysis of the pooled TULIP-1/TULIP-2 trials, 15.3% of anifrolumab-treated patients (300 mg every 4 weeks (Q4W)) achieved DORIS remission at Week 52, compared with 6.6% of patients treated with placebo (odds ratio (OR) (95% CI): 2.6 (1.6 to 4.3), p=0.0002). DORIS remission was achieved by significantly more patients in the anifrolumab group compared with the placebo group starting at Week 32, suggesting an earlier attainment of DORIS remission with anifrolumab treatment.